For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Research Pulse: November 2026

This edition covers the past week of regulatory and development news on compounds in the Research Library. HHS published a policy on compounding six peptides, and the week also brought a citizen petition, a Lilly pipeline update and a new orthopaedic review.

HHS publishes an enforcement discretion policy on six peptides

HHS issued a notice on 28 October, published 30 October, on 503A compounding with BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 [1]. HHS says it does not intend to act against compounders meeting listed conditions until a final rule addresses each substance. The notice describes the policy as interim, draft and non-binding, and written comments run for two weeks after publication [1]. It does not approve any product or add any peptide to the 503A bulks list [3].

The notice names state-licensed pharmacies, Federal facilities and licensed physicians, and does not name 503B outsourcing facilities [1]. It does not authorize research-use-only supply, and it says one aim is to discourage use of certain foreign-supplied research-use-only peptides [1]. Emideltide (DSIP), which the advisory committee voted against in July, is not listed [1][2][3].

BPC-157 reference page → · FDA Peptide Regulatory Tracker →

Citizen petition asks FDA not to allow compounding of the July peptides

The Partnership for Safe Medicines published a citizen petition on 27 October asking FDA not to allow compounding of the peptides reviewed in July, whether by regulation, Category 1 placement or enforcement discretion [4]. The group also asks FDA not to rely on the July advisory committee, arguing it was improperly constituted [4]. This is the petitioner’s position. FDA has not published a response that we could find.

TB-500 reference page →

Lilly’s third-quarter report lists updates on tirzepatide, retatrutide and orforglipron

Lilly’s 29 October results list a new FDA indication for Mounjaro (tirzepatide, first approved 2022): reducing cardiovascular risk in adults with type 2 diabetes [5]. The release also lists company-reported human trial readouts. They are a head-to-head Phase 3 trial of retatrutide against a marketed GLP-1 drug in type 2 diabetes, and an orforglipron study in the same population [5]. Retatrutide remains investigational.

Tirzepatide reference page → · Retatrutide reference page → · Orforglipron reference page →

Orthopaedic journal reviews BPC-157 and thymosin beta-4

The Journal of the American Academy of Orthopaedic Surgeons published a narrative review online on 27 October covering BPC-157, thymosin beta-4 and TB-500 as investigational peptides [6]. A narrative review summarizes existing literature and adds no new primary data. It is a sign that the topic has reached mainstream orthopaedic publishing.

BPC-157 reference page → · TB-500 reference page →

How this round-up is made

The Kalibra Research Desk reports on published research and regulatory actions. It does not give medical, dosing or usage advice, and nothing here describes use in people or animals. Kalibra Labs products are for laboratory research use only.

Sources

  1. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192. 30 Oct 2026. Link
  2. U.S. Department of Health and Human Services. Appendix B: Peptide Identities and Justifications. Oct 2026. Link
  3. Foley & Lardner LLP. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. 30 Oct 2026. Link
  4. Partnership for Safe Medicines. Citizen petition post. 27 Oct 2026. Link
  5. Eli Lilly and Company. Third-quarter 2026 financial results. 29 Oct 2026. Link
  6. Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice. J Am Acad Orthop Surg. 27 Oct 2026. Link
  7. Holland & Knight LLP. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. 16 Oct 2026 (timeline dates). Link
0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top